MEDICAGO
16.12.2021 20:02:09 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant. Medicago is seeking review and approval for the vaccine candidate for indication in healthy adults, aged 18 years and above.
“We are pleased to submit our Phase 3 data as the final portion of the rolling submission for our COVID-19 vaccine candidate for review,” said Dr. Judith Atkins, Vice-President of Regulatory Affairs at Medicago. “We are grateful to Health Canada for their review, and we hope this brings Canadians and the world one step closer to having greater vaccine diversity.”
Thomas Breuer, Chief Global Health Officer, GSK, added: “We are one step closer to our goal of making this innovative adjuvanted, plant-based vaccine available. As a refrigerator-stable option that builds on our established adjuvant technology, we are hopeful it will play an important role in the efforts to overcome the COVID-19 pandemic.”
The New Drug Submission for COVID (NDS-CV) process allowed the submission of nonclinical sections, quality, clinical safety, and efficacy information as they became available for Health Canada’s immediate review to accelerate the overall review process. Submitting the Phase 3 data completes the submission process.
The regulatory filing process for the COVID-19 vaccine candidate has been initiated with the FDA (US) and MHRA (UK). Preliminary discussion is underway with the WHO for preparation of the submission. A Phase 1/2 trial has also been initiated in Japan where Medicago plans to submit for regulatory approval in combination with the Phase 2/3 global study results next spring. The vaccine candidate has not yet been approved by any health authorities.
“If authorized, Medicago’s COVID-19 vaccine would be the world’s first ever plant-based vaccine approved for human use,” said Takashi Nagao, CEO and President of Medicago. “It would also be the first Canadian vaccine approved in over 20 years, signaling a powerful step forward for Canada’s vaccine preparedness strategy.”
About Medicago
Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. For more information: www.medicago.com
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC) Group, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas under its Medium-Term Management Plan 21-25 and is also working to develop new modalities of vaccines. MTPC Group will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. For further information please visit https://www.mt-pharma.co.jp/e/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005780/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Recognized Among Top 5% Globally for Sustainability Performance with EcoVadis Gold Rating11.2.2026 13:00:00 CET | Press release
Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has earned the EcoVadis Gold rating, placing the company among the top 5% of organizations assessed globally for sustainability performance in their sector. EcoVadis is one of the world’s most widely used business sustainability assessment platforms, evaluating companies across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The Gold rating reflects not only the presence of sustainable policies but also the robustness of management systems, documentation, and implementation practices, as evaluated by EcoVadis across Americhem’s global operations. The EcoVadis Gold rating follows Americhem’s prior Silver ratings in recent years and reflects continued strengthening of environmental stewardship, governance, and management systems across the organization. “This recognition reflects how our teams run the bus
Echodyne to Open Major New Manufacturing Facility to Meet Rapidly Growing Global Demand11.2.2026 13:00:00 CET | Press release
$40M investment in 86,350-square-foot facility in Washington State, USA Annual production capacity of >30,000 radars across product lines More than 200 employees at full capacity Start of production in summer 2026 Echodyne, the radar platform company, today announces a major near-term expansion in its advanced radar production capacity. Echodyne’s new 86,350-square-foot facility will provide enough manufacturing and warehouse space to produce and ship more than 30,000 radars per year. The company’s modular manufacturing approach allows production capacity to flex to match varying demand across product lines as well as seamlessly introducing new product lines and capabilities. The investment reflects Echodyne’s continued commitment to: enhancing security and safety as UxS become ubiquitous on the battlefield and in society in general, staying ahead of the accelerating demand in the U.S. and in Allied countries around the globe, and strengthening America’s defense industrial base. Counte
Agentic AI Consulting: Sia Accelerates Its Development with More Than 400 Agents on Its Agent Store11.2.2026 12:17:00 CET | Press release
Sia, an international consulting group specializing in strategy, management, and AI, has reached a milestone in its Agentic AI journey. Born in the digital era, the firm now leverages the expertise of more than 3,000 consultants in 19 countries to help organizations scale AI-driven transformation. From GenAI to an Agent Store for All Industries and Functions After unveiling its Generative AI platform to clients in June 2023, the firm announced the launch of its Agent Store in September 2025. Built on a learn-by-design approach, Sia’s Agent Store grew from 50 AI agents to over 400 available for direct consultation, with over a dozen Minimum Viable Products ready for demonstration. Originally introduced as SiaGPT, the platform is now accessible via siagents.ai, reflecting the transition from custom GPTs to fully agentic services. Sia’s AI agents cover a wide range of industries such as Finance, Energy, Public Sector, Healthcare, and Retail and Consumer Goods, and address all corporate fu
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 2611.2.2026 12:00:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics thro
OpenX Strengthens EMEA Leadership with Appointment of Natalie Fisher-Brown11.2.2026 11:05:00 CET | Press release
As RVP, EMEA Buyer Development, the established adtech leader will lead buy-side sales and account management across the region. OpenX Technologies, Inc., one of the world’s leading omnichannel supply-side platforms, today announced the appointment of Natalie Fisher-Brown as Regional Vice President, EMEA Buyer Development. Fisher-Brown will lead, develop, and manage OpenX’s buy-side sales and account management organisations across EMEA, with a focus on strengthening key strategic markets and driving long-term growth for partners. In this new role, Fisher-Brown will oversee the development of senior-level relationships across agencies and brands. She will work closely with well-established and emerging partners to build strategic collaborations that support responsible innovation and sustainable growth. Fisher-Brown’s appointment follows recent hires in France and Germany, reflecting OpenX’s continued investment in market expansion as it evolves the role of the SSP to meet the needs of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom